Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer

Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Bibliographic Details
Main Author: Hoque, Ismoth Ara
Other Authors: Azam, Faruque
Format: Thesis
Language:English
Published: Brac University 2024
Subjects:
Lung cancer
PFS
ORR
NSCLC subtypes
Lungs > Cancer
Clinical trials > Statistical methods
Online Access:http://hdl.handle.net/10361/23164
id 10361-23164
record_format dspace
spelling 10361-231642024-06-05T21:01:20Z Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer Hoque, Ismoth Ara Azam, Faruque School of Pharmacy, Brac University Lung cancer PFS ORR NSCLC subtypes Lungs--Cancer Clinical trials--Statistical methods This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 25-26). The American Cancer Society estimates that lung cancer is the most common type of cancer and nearly 25% cancer deaths result from lung cancer, of which three subtypes account for 80% of cases. This is the rationale behind our study's selection of NSCLC subtypes. Moreover, drugs approved after passing clinical trials. Phase II clinical studies rely on "interim" data about safety and efficacy, enabling quicker drug approval. However, patient’s diversity is a cause of treatment failure, as the risk of adverse events or treatment failure can be influenced by individual genetic variation. To solve this, finding an efficacy endpoint (PFS, ORR, OS) type from clinical studies allow the effectiveness of treatment to be quantified. In our study, we gathered effective endpoints and analysed to determine whether any relationships existed and if so, constructed a predictive model with the best predictor endpoint Ismoth Ara Hoque B. Pharmacy 2024-06-05T09:32:47Z 2024-06-05T09:32:47Z ©2023 2023-03 Thesis ID 18346044 http://hdl.handle.net/10361/23164 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 57 pages application/pdf Brac University
institution Brac University
collection Institutional Repository
language English
topic Lung cancer
PFS
ORR
NSCLC subtypes
Lungs--Cancer
Clinical trials--Statistical methods
spellingShingle Lung cancer
PFS
ORR
NSCLC subtypes
Lungs--Cancer
Clinical trials--Statistical methods
Hoque, Ismoth Ara
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
description This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
author2 Azam, Faruque
author_facet Azam, Faruque
Hoque, Ismoth Ara
format Thesis
author Hoque, Ismoth Ara
author_sort Hoque, Ismoth Ara
title Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
title_short Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
title_full Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
title_fullStr Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
title_full_unstemmed Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
title_sort efficacy analysis and prediction in phase ii clinical trials of non-small cell lung cancer
publisher Brac University
publishDate 2024
url http://hdl.handle.net/10361/23164
work_keys_str_mv AT hoqueismothara efficacyanalysisandpredictioninphaseiiclinicaltrialsofnonsmallcelllungcancer
_version_ 1814307443046350848

Similar Items